Compare ProShares Bitcoin ETF (BITO) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Bitcoin ETF vs Boston Scientific Corporation — how do they compare? ProShares Bitcoin ETF trades at $10.97 (market cap $1.60B), while Boston Scientific Corporation trades at $45.05 (market cap $64.33B). The key difference: Boston Scientific Corporation is far larger — about 40.2× ProShares Bitcoin ETF's market cap, and ProShares Bitcoin ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Bitcoin ETF for 35 Days and Boston Scientific Corporation for 80 Days on average.
| BITO | BSX | |
|---|---|---|
Market Cap | $1.60B | $64.33B |
Volume | 73,964,313 | 12,408,372 |
Sector | Crypto-linked | Health |
52-Week High | $18.93 | $104.98 |
52-Week Low | $7.98 | $41.58 |
Typical Hold Time | 35 Days | 80 Days |
Enterprise Value | — | $76.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITO trades at $10.92, up 0.37% today, with a bearish technical signal overall despite bullish moving averages. Recent news highlights large put option activity and concerns over dividend reductions and underperformance versus newer ETFs. The stock faces mixed sentiment amid regulatory uncertainty and competitive pressures.
The outlook remains cautious due to weak distributions and ETF competition. Risks include regulatory delays and volatile inflows. Analyst sentiment is negative, with some advising avoidance, though tactical traders may find utility. Key support and resistance cluster around $11.
Boston Scientific (BSX) trades at $44.96, up 1.27% with strong fundamental performance including 14.43% net income margin and consistent earnings beats. The stock shows bullish technical signals despite mixed indicators, with revenue growing from $12.7B in 2022 to $20.1B in 2025. Recent developments include operational recovery post-cyberattack and strategic acquisitions driving long-term growth prospects across medical technology segments.
BSX presents a compelling investment case with robust profitability, analyst consensus of $61.48 price target (37 buy ratings), and improving cash flow trends. Key risks include near-term pressure in electrophysiology segments and competitive challenges, but the company's diversified MedSurg portfolio and upcoming product launches support positive long-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ProShares Bitcoin ETF
BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.
Read more on BITO →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
